Newer systemic antifungal drugs for the treatment of onychomycosis.
Onychomycosis, the infection of the nail unit by any fungus, far from being just a cosmetic problem, has significant psychological, physical, social, and financial implications. Further, it has experienced a dramatic rise in incidence in recent years. The introduction of newer systemic antifungal drugs (itraconazole, fluconazole, and terbinafine) offer an increased cure rate, a broader spectrum of activity, shortening of the treatment period, and increased safety, compared with the traditional systemic antifungal drugs griseofulvin and ketoconazole. Because the fungi involved are difficult to eradicate from the floors of communal bathing facilities, where the infection is often contracted, an effective treatment is likely to have a significant impact on disease prevalence.